Atlas Venture
http://www.atlasventure.com/Atlas Venture is a venture capital firm that invests in early stage technology and life sciences businesses. Since the firm’s founding in 1980, the firm has helped build over three hundred companies. Since 1995, forty seven of its investments have been acquired and more than forty have gone public, with an aggregate market capitalization of over $20 billion.
View Older Stories View More Recent Stories
-
Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
-
Rectify Pharma to Present Translational Data on Novel Approach to Treat Chronic Kidney Disease and Vascular Calcification at ERA 2025
-
Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia
-
Form 13F-HR Atlas Venture Life Scien For: Mar 31
-
Rectify Pharma Presents Translational Data for Novel Positive Functional Modulator Demonstrating Improved Biliary and Liver Health at EASL 2025
-
Form 13F-NT Atlas Venture Associates For: Mar 31
-
Form 13F-NT Atlas Venture Associates For: Mar 31
-
Form 13F-NT Atlas Venture Fund VIII, For: Mar 31
-
Form 13F-HR Atlas Venture Advisors, For: Mar 31
-
Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Associates XII, L.P.
-
Form 144 Jade Biosciences, Inc. Filed by: Atlas Venture Fund XII, L.P.
-
Form SCHEDULE 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
-
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
-
Rectify Pharma to Share Preclinical Data Highlighting Progress in Hepatobiliary Program at EASL 2025
-
Scion Life Sciences Expands Team with Appointment of Three Venture Partners
-
Remix Therapeutics Appoints Linda C. Bain to Board of Directors
-
Rectify Pharma Announces Publication of BSEP Transporter Biophysical Characterization in Communications Biology
-
Angelini Ventures Appoints Seasoned Life Sciences Investor, Dr. Regina Hodits, as Managing Director
-
Be Biopharma Announces Appointment of Susan Abu-Absi, Ph.D. as Chief Operating Officer
-
NAYA Biosciences (NAYA) nominates new Board members
-
NAYA Biosciences Announces Nomination of New Board Members
-
Form SCHEDULE 13D Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
-
LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
-
Form 13F-NT Atlas Venture Associates For: Dec 31
-
Form 13F-NT Atlas Venture Associates For: Dec 31
-
Form 13F-NT Atlas Venture Fund VIII, For: Dec 31
-
Form 13F-HR Atlas Venture Advisors, For: Dec 31
-
Form 4 Sionna Therapeutics, For: Feb 10 Filed by: Atlas Venture Associates Opportunity II, LLC
-
Form 3 Sionna Therapeutics, For: Feb 06 Filed by: Atlas Venture Fund XI, L.P.
-
Form 13F-HR Atlas Venture Life Scien For: Dec 31
-
Be Biopharma Announces Publication of Manuscript in the Molecular Therapy Journal Demonstrating In Vivo Engraftment and Tracking of Ex-vivo-Generated Plasma Cells in Non-Human Primates
-
Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
-
Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
-
Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
-
Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment
-
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company
-
Lifordi Immunotherapeutics Appoints Matthew W. McClure, M.D., as Chief Medical Officer
-
Arkuda Therapeutics Announces Option Exercise and Asset Purchase
-
Actio Biosciences Expands Leadership Team with Appointment of Cayce Denton as Chief Financial Officer
-
Be Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines
-
Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform at ASH 2024
-
Form D Atlas Venture Fund XIV,
-
Atlas Venture Announces $450 Million Fund XIV
-
K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American Society of Hematology (ASH) Annual Mee
-
Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024
-
Form SC 13G/A Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
-
Form SC 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
-
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
-
Form SC 13G/A Day One Biopharmaceutica Filed by: Atlas Venture Fund XI, L.P.

